• Pressemitteilung BoxID 499835

Genentech and Pfizer Share CDx Success Insights at the 4th Molecular Diagnostics for Cancer Drug Development in Boston

(PresseBox) (London, UK, ) The final agenda has been released for the 4th Molecular Diagnostics for Cancer Drug Development meeting (Boston, June 25th - 28th 2012).

The 3 day agenda features 31 expert speakers including the key project leaders of Zelboraf (Genentech) and Xalkori (Pfizer) on overcoming the scientific and commercial hurdles of targeting a drug to a specific patient subpopulation, and how they gained regulatory approval of their companion diagnostics last year.

They join oncology and diagnostics experts representing: Clovis Oncology, MD Anderson Cancer Center, Johnson & Johnson, National Cancer Institute, Astellas Pharma, Fred Hutchinson Cancer Research Center, The Biomarkers Consortium, Novartis, Daiichi-Sankyo, FDA, ImmunoGen, Bristol-Myers Squibb, Morphotek, Eisai, Bayer, Dana-Farber Cancer Institute, AVEO Pharmaceuticals, Celgene and Merck.

Visit the event website or download the brochure to see the full speaker line up and agenda.

Diese Pressemitteilungen könnten Sie auch interessieren

Schmerzmanagement bei Kindern mit Vorerkrankungen: Ein systematisches Vorgehen ist gefragt

, Medizintechnik, 3M Deutschland GmbH

Anlässlich des 12. Kongresses der European Academy of Paediatric Dentistry organisierte 3M ESPE im Juni 2014 im polnischen Sopot ein Symposium...

Home Monitoring Hayat Kurtarır ve Maliyet Azaltır

, Medizintechnik, BIOTRONIK

Uzmanlar, Home Monitoring Teknolojisinin faydalarını hastalar, hastaneler ve muhataplar açısından ilk defa, Avrupa Kardiyoloji Derneğinin yıllık...

The Lancet: Uzaktan Takip, ICD ve CRT-D hastalarının hayatını kurtarabilir

, Medizintechnik, BIOTRONIK

Kardiyovasküler medikal teknoloji alanında önde gelen üreticilerden BIOTRONIK, bugün IN-TIME çalışmasının sonuçlarının The Lancet tıp dergisinde...

Disclaimer